Please note that for mobiles we stream the presentation slides and audio of the speaker.
Heptares Therapeutics discovers and develops new medicines targeting GPCRs (G protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. The company is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that target historically undruggable or challenging GPCRs. Its integrated discovery platform has enabled it to generate a broad pipeline of novel drugs directed towards these targets, which it is developing for the treatment of a number of diseases.
This lecture was part of an event called ‘Medical Innovations Summit’ at The Royal Society of Medicine in London.
Date of lecture: 5th July 2014
This video is available for iPad via Safari